Stock EGTX EGETIS THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Egetis Therapeutics AB

Equities

EGTX

SE0003815604

Market Closed - Nasdaq Stockholm
Other stock markets
 17:00:00 28/06/2024 BST 		5-day change 1st Jan Change
4.67 SEK -6.32% Intraday chart for Egetis Therapeutics AB -25.52% -16.31%
06-20 Transcript : Egetis Therapeutics AB - Special Call
06-19 Egetis Therapeutics AB Announces Topline Results of the Phase 2 Triac Trial II with Emcitate for MCT8 Deficiency CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Egetis announces topline results of the Phase 2 Triac Trial II with Emcitate® (tiratricol) for MCT8 deficiency
AQ
Egetis awarded Promising Innovative Medicine designation in the UK for Emcitate® (tiratricol) for treatment of MCT8 deficiency
AQ
Bulletin from Egetis Therapeutics’ Annual General Meeting 2024
AQ
Egetis Therapeutics Q1 2024 - EU launch closing in
AQ
The Nomination Committee adjusts its proposal for the annual general meeting of Egetis Therapeutics AB (publ)
AQ
Egetis Therapeutics' : 2023 Annual Report published
PU
Egetis Therapeutics’ 2023 Annual Report published
AQ
Egetis Therapeutics : NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)
PU
Egetis Therapeutics - Continued progress in Q4
AQ
Egetis Therapeutics : – Corporate Presentation December 2023
PU
Egetis recruits Laetitia Szaller as General Counsel and Head of Compliance
AQ
Egetis highlights recent major milestones, status of ReTRIACt trial and gives a corporate update at Investor Day in Stockholm today
AQ
Egetis’ Investor Day on December 19: Agenda and Registration Details
AQ
Egetis provides update on disease awareness and the Expanded Access Program for tiratricol (Emcitate) in the USA
AQ
Save the Date: Egetis to host Investor Day on December 19, 2023
AQ
Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan
AQ
Egetis Therapeutics - All eyes on eventful 2024
AQ
Egetis Therapeutics has resolved on directed issues of warrants and a convertible bond within the framework of the drawdown of Tranche A of the previously communicated debt financing
AQ
Egetis recruits Desiree Luthman as Vice President Global Regulatory Affairs
AQ
Egetis’ Nomination Committee for the 2024 Annual General Meeting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EGTX Stock
  4. News Egetis Therapeutics AB
  5. Press Releases